Overview
Pancreatic polypeptide is a 36–amino acid endogenous peptide hormone discovered in the 1970s and secreted by gamma cells, also known as PP or F cells, of the islets of Langerhans, predominantly located in the head of the pancreas. It acts as an important feedback inhibitor of pancreatic secretion after meals, especially protein-rich meals, and is released in a biphasic manner.
Pancreatic polypeptide plays a role in regulating digestion by inhibiting pancreatic exocrine secretion, gastric emptying, gallbladder contraction, and bile secretion. It is a linear peptide related to neuropeptide Y and peptide YY, with a short plasma half-life of about six minutes, and contributes to energy balance and appetite regulation.
Symptoms
Pancreatic polypeptide itself does not cause specific symptoms under normal physiological conditions, but abnormal levels are associated with clinical manifestations of underlying disorders.
Excess secretion may be seen in pancreatic neuroendocrine tumors known as PPomas, which can present with diarrhoea, abdominal pain, and weight loss. Elevated levels may also be associated with gastrointestinal disturbances, diabetes, and metabolic imbalance. Altered PP responses can reflect dysfunction of pancreatic regulation, appetite control, and digestive processes.
Causes
Increased pancreatic polypeptide levels are commonly caused by pancreatic endocrine tumors, gastrointestinal disorders, diabetes mellitus, and non-fasting states. Elevated levels may also be seen as a normal physiological response after meals or during sham feeding when the vagus nerve is intact.
Reduced or abnormal secretion may occur due to pancreatic damage, chronic pancreatitis, vagal nerve injury, or autonomic dysfunction. Drug interference, including the use of insulin, anticholinergics, or somatostatin analogues, can also alter pancreatic polypeptide levels.
Risk Factors
Risk factors for abnormal pancreatic polypeptide levels include pancreatic neuroendocrine tumors, chronic pancreatic disease, diabetes mellitus, and gastrointestinal disorders. Age is an important factor, as normal PP levels increase progressively with advancing age.
Non-fasting status, autonomic nerve dysfunction, previous pancreatic or gastrointestinal surgery, and use of medications affecting pancreatic secretion increase the likelihood of altered PP levels. Improper sample handling, haemolysis, and delayed serum separation may also affect results.
Prevention
Prevention of abnormal pancreatic polypeptide levels focuses on early identification and management of pancreatic and metabolic disorders. Proper fasting before testing helps avoid falsely elevated results. Monitoring patients with known pancreatic disease, diabetes, or suspected neuroendocrine tumors allows timely diagnosis and follow-up.
Careful evaluation of medications and avoidance of factors that interfere with autonomic regulation support accurate assessment. Appropriate clinical monitoring helps prevent complications related to pancreatic dysfunction and metabolic imbalance.
